New trials and results in systemic treatment of HCC María Reig, Leonardo Gomes da Fonseca, Sandrine Faivre  Journal of Hepatology  Volume 69, Issue 2, Pages 525-533 (August 2018) DOI: 10.1016/j.jhep.2018.03.028 Copyright © 2018 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Outcome prediction of patients according to the treatment options received after sorafenib interruption or radiological tumour progression. Overall survival in patients who developed early dermatological events during sorafenib treatment and who are candidates to receive regorafenib as second-line therapy is also mentioned. Journal of Hepatology 2018 69, 525-533DOI: (10.1016/j.jhep.2018.03.028) Copyright © 2018 European Association for the Study of the Liver Terms and Conditions